APRINOIA Therapeutics Appoints Mark S. Shearman, Ph.D., as Chief Executive Officer

CAMBRIDGE, Mass., Aug. 28 (Korea Bizwire) — APRINOIA Therapeutics (“APRINOIA”), a global clinical-stage biopharmaceutical company developing novel therapeutics and precision diagnostics for the treatment of neurodegenerative diseases such as Alzheimer’s Disease (“AD”), Parkinson’s Disease (“PD”), and certain rare dementia and movement disorders, announced today that its Board of Directors has appointed Mark S. Shearman, Ph.D. [...]